

**6 entries found for *diagnostic*.**

**di·ag·nos·tic** (s k)  
*adj.*

Of, relating to, or used in a diagnosis.

Serving to identify a particular disease; characteristic.

*n.*

The art or practice of medical diagnosis. Often used in the plural with a singular verb.

A symptom or a distinguishing feature serving as supporting evidence in a diagnosis.

An instrument or a technique used in medical diagnosis.

\* accessed from dictionary.com



National  
Library  
of Medicine



My NC  
[Sign In] [Regis]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Book

Search PubMed

for

Go

Clear

 Limits   Preview/Index   History   Clipboard   Details

Q132. 108

Limits: Publication Date from 1999 to 1999

Display Abstract

Show 20

Sort by

Send to

Examiner  
copy  
reference #2

All: 1 Review: 0

1: Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11949-53. Related Articles, Links

[FREE full text article at  
www.pnas.org](http://www.pnas.org)

[FREE full text article  
in PubMed Central](#)

### Detection of glutamine synthetase in the cerebrospinal fluid of Alzheimer diseased patients: a potential diagnostic biochemical marker.

Gunnerson D, Haley B.

Department of Biochemistry, College of Pharmacy, University of Kentucky, Lexington 40536-0084.

In this report, 8- and 2-azidoadenosine 5'-[gamma-32P]triphosphate were used to examine cerebrospinal fluid (CSF) samples for the presence of an ATP binding protein unique to individuals with Alzheimer disease (AD). A 42-kDa ATP binding protein was found in the CSF of AD patients that is not observed in CSF from normal patients or other neurological controls. The photolabeling is saturated with 30 microM 2-azidoadenosine 5'-[gamma-32P]triphosphate. Photoinsertion can be totally prevented by the addition of 25 microM ATP. Photoinsertion of 2-azidoadenosine 5'-triphosphate into the protein is only weakly protected by other nucleotides such as ADP and GTP, indicating that this is a specific ATP binding protein. A total of 83 CSF samples were examined in a blind manner. The 42-kDa protein was detected in 38 of 39 AD CSF samples and in only 1 of 44 control samples. This protein was identified as glutamine synthetase [GS; glutamate-ammonia ligase; L-glutamate:ammonia ligase (ADP-forming), EC 6.3.1.2] based on similar nucleotide binding properties, comigration on two-dimensional gels, reaction with a polyclonal anti-GS antibody, and the presence of significant GS enzyme activity in AD CSF. In brain, GS plays a key role in elimination of free ammonia and also converts the neurotransmitter and excitotoxic amino acid glutamate to glutamine, which is not neurotoxic. The involvement of GS, if any, in the onset of AD is unknown. However, the presence of GS in the CSF of terminal AD patients suggests that this enzyme may be a useful diagnostic marker and that further study is warranted to determine any possible role for glutamate metabolism in the pathology of AD.

Related Resources  
Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

PMID: 1361232 [PubMed - indexed for MEDLINE]

Display  Abstract

Show 20



Sort by



Send to

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

May 2 2005 17:45:08